Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Liaoning Cheng Da Co., Ltd. (600739.SS)
Dalian, CN
Founded in Dalian, China, in 1991, Liaoning Cheng Da Co., Ltd. operates a diverse business portfolio both domestically and across international markets. Its extensive activities span four core areas: trading, medicine and healthcare, financial investment, and energy development. The company's trading arm handles a wide array of goods, including textiles, apparel, chemicals, coal, aquatic products, timber, and steel, while also providing medical insurance. Its robust medicine and healthcare division focuses on the research, development, production, and marketing of human and veterinary vaccines. This segment also manages pharmaceutical retail, wholesale, and logistics distribution, offers medical enterprise management consulting, and sells medical equipment. Furthermore, it provides services in medical technology, computer hardware and software development, technology consulting, transfer, and general technical support. In the financial sector, Liaoning Cheng Da Co., Ltd. engages in securities and fund activities, and for energy development, it is involved in oil shale projects.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.19% | -3.15% | -9.58% | -11.59% | -8.50% | -3.76% | +1.70% | -20.36% | -49.74% | -29.72% | +1,406.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%-12.4% Q1'26: -22.5% (vs Q1'25)
-
EPS growth Medical - Distribution: +4.9%+248.6% ★ Q1'26: +57.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-12.5% Q1'26: -11.1% (vs Q1'25)
-
EBIT margin Medical - Distribution: +3.0%-6.6% Q1'26: -2.8% (vs Q1'25)
-
ROIC Medical - Distribution: +5.7%-1.4% Q1'26: -0.6% (vs Q1'25)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-52.53× Q1'26: -64.62× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-25 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 96.5K | 0.17% |
| 2 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 96.5K | 0.17% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 22.5K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 50.7K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.50M | 0.06% |
| 6 | Vanguard Total World Stock ETF VT | 0.00% | 707.7K | 0.06% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.44M | 0.05% |
| 8 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 13.9K | 0.04% |
| 9 | Vanguard FTSE All-World ex-US ETF VEU | 0.00% | 299.6K | 0.04% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chuang Qiu | Vice President & Secretary of the Board | — | male |
| Heng Li | Compliance Director | — | male |
| Lu Wang | Accounting Supervisor & Chief Financial Officer | — | female |
| Peng Zhang | Human Resources Director | — | female |
| Shanwei Zhang | President & Director | — | male |
| Yue Zhou | Vice President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600739.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
